New radioactive drug targets Hard-to-Treat prostate cancer
NCT ID NCT05983198
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to seek out and destroy cancer cells that have a specific marker called PSMA. The trial will check the drug's safety and how well it works in 33 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
225Ac-PSMA-R2 (a radioactive drug that targets prostate cancer cells)
What this could lead to
If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 33 participants, so results may not apply broadly. The drug is radioactive and may cause side effects like damage to healthy tissues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Novartis Investigative Site
Darlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
Montreal, Quebec, H2X 1R9, Canada
-
Novartis Investigative Site
Dijon, Cote D Or, 21034, France
-
Novartis Investigative Site
Clermont-Ferrand, 63011, France
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Vandœuvre-lès-Nancy, 54511, France